Ratify (Alliance 10603): Prognostic Impact of FLT3 Tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin Plus Standard Chemotherapy
- Citation:
- HemaSphere vol 3 (suppl 1) 79-80
- Meeting Instance:
- EHA 2019
- Year:
- 2019
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- 3327
- Pharmas:
- Novartis
- Grants:
- U10CA180821, U10CA180882, U24CA196171
- Corr. Author:
- Authors:
- Maria Teresa Voso Richard A. Larson Thomas W Prior Guido Marcucci Dan Jones Jürgen Krauter Michael Heuser Serena Lavorgna Josep Nomdedeu Susan M. Geyer Rebecca B. Klisovic Andrew Wei Jorge Sierra Miguel A. Sanz Joseph M. Brandwein T. M. M de Witte Joop H. Jansen Dietger Niederwieser Frederick R. Appelbaum Bruno C Medeiros Martin S. Tallman Richard F. Schlenk Arnold Ganser Sergio Amadori Yuan Cheng YinMiao Chen Eva Tiecke Christian Thiede Konstanze Döhner Hartmut Döhner Richard M. Stone Clara D. Bloomfield Francesco Lo-Coco.
- Networks:
- CA043, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-OH007
- Study
- CALGB-10603
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: